基因检测公司 23andMe 裁员 40% 并停止治疗项目以节省成本。 Genetic testing firm 23andMe cuts 40% of jobs and halts therapeutic programs to save costs.

基因检测公司 23andMe 正在裁员 40%，影响约 200 个工作岗位，并停止其治疗项目的开发，以节省成本并重新专注于其核心业务。 Genetic testing company 23andMe is cutting its workforce by 40%, affecting around 200 jobs, and halting the development of its therapeutic programs in a bid to save costs and refocus on its core business. 首席执行官 Anne Wojcicki 计划探索战略替代方案，例如公司疗法的许可和资产出售。 CEO Anne Wojcicki plans to explore strategic alternatives like licensing and asset sales for the company’s therapeutics. 重组的目标是每年节省超过 3500 万美元。 The restructuring aims to save over $35 million annually.